
A study of 885 mHSPC patients suggests a new definition of castration-resistant prostate cancer (CRPC) more accurately reflects prostate cancer biology after conventional vs. upfront ARSI therapy. While upfront ARSI improves CRPC-free and cancer-specific survival, conventional CRPC definitions may misrepresent prognosis. The proposed definition offers clearer survival comparisons.
Like
Save
Share